Immunic
IMUX
69 hedge funds and large institutions have $149M invested in Immunic in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 14 reducing their positions, and 9 closing their positions.
699% more call options, than puts
Call options by funds: $2.58M | Put options by funds: $323K
100% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 14
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
5% more funds holding
Funds holding: 66 → 69 (+3)
0.57% more ownership
Funds ownership: 4.12% → 4.7% (+0.57%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $153M → $149M (-$3.83M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.82M |
| 3 |
BlackRock
New York
|
+$3.91M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.67M |
| 5 |
Two Sigma Advisers
New York
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$4.67M |
| 2 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$2.28M |
| 3 |
Millennium Management
New York
|
-$2.15M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.8M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$930K |
IMUX Hedge Fund Activity: Q4 2020 in Review
69 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2020, worth a combined $149M — down 2.5% from $153M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new IMUX positions and 9 closed out — a net gain of 4 holders — while 28 added to existing stakes and 14 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $7.44M. The largest seller was Invesco, exiting entirely with an estimated $4.67M sold.
- 69 institutional investors held Immunic (IMUX) as of Q4 2020, up from 66 in Q3 2020.
- Funds reported $149M of Immunic stock for Q4 2020, down 2.5% quarter-over-quarter.
- 13 funds opened new Immunic positions in Q4 2020 and 9 closed out, a net change of +4 holders.
- The largest Immunic buyer in Q4 2020 was T. Rowe Price Associates, an estimated $7.44M added.
- The largest Immunic seller in Q4 2020 was Invesco, an estimated $4.67M sold.
Based on aggregated 13F filings for Q4 2020.